ClinicalTrials.gg
Active, not recruitingNCT05316324Updated Feb 17, 2026

A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction

A Phase 3 interventional study of Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM) and Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM) in Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 2 sites in United States. Open to female participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center — 47 open to participants now, 98 under way, 3 of them phase 3. Breast Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
14th of 156
353 · median 51
Started
2022
with 9 others
Phase 3
6 of 253
1 open now
Primary completion
2027-03
later than 19 of 97 live
Registered
209th of 253
by date

Among the 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 14th largest by enrollment of the 156 interventional ones that give a count, is one of 10 that started in 2022, is one of 6 in phase 3, reaches primary completion later than 19 of the 97 other live ones, and was the 209th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

47 of the 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 4 countries. Recruiting first, the newest first:

42 more — sign in →

By country, each count listing its studies:

All 47 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 21 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The researchers are doing this study to look at the number of complications that occur immediately after prepectoral breast reconstruction when Acellular Dermal Matrix (ADM) is used compared to when ADM is not used. These complications include infections, the need for Tissue Expander (TE) or implant removal, and other conditions that lead to additional surgery.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Acellular Dermal Matrix
  • Breast Reconstruction
  • Mastectomy
  • 22-071
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 21-60 years
  • Planning to undergo unilateral or bilateral mastectomy, prophylactically or to treat breast cancer
  • Planning to undergo immediate two-stage prosthetic breast reconstruction with TE placement as the first stage
  • Planning to undergo nipple-sparing or skin-sparing mastectomy
  • Adequate mastectomy skin perfusion or adequate perfusion but nonviable mastectomy skin that can be excised (≤4 cm) at the defect margins with otherwise adequate perfusion
  • Intraoperative confirmation of prepectoral plane viability by operating physician

Exclusion criteria

Exclusion Criteria:

  • History of radiotherapy to the operative breast
  • Current smoker
  • Non-English speaking patients
  • Planning to undergo direct-to-implant reconstruction
  • Prior sternotomy
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Prepectoral Breast Reconstruction with ADM

    Procedure: Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)

  • Experimental
    Prepectoral Breast Reconstruction without ADM

    Procedure: Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)

Interventions

  • ProcedurePrepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)

    Prepectoral Breast Reconstruction with (ADM)

  • ProcedurePrepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)

    Prepectoral Breast Reconstruction without ADM

06

What researchers measure

Primary outcomes

  1. Percentage of patients who experience major complications

    Listed below are definitions for 90-day major complications for TEs (i.e., infection, explantation, and reoperation for any cause, including mastectomy flap necrosis): * Infection defined as: * Any event requiring the restart of antibiotics (oral or intravenous) after completion of initial perioperative antibiotics * Admission to the hospital for signs and symptoms of cellulitis (redness on breast mound) requiring antibiotics * Purulent drainage from the surgical site or incision * Explantation defined as the need for removal of a TE for any cause * Reoperation defined as skin excision performed in either the clinic or the operating room for mastectomy skin flap necrosis, surgical incision dehiscence, pending skin breakdown or another surgical complication

    Time frame: 90 days

Secondary outcomes

  1. Estimate rates of minor complications (specifically seroma)

    Minor complication for (Tissue Expanders) TEs are defined as: o Seroma: Clinically significant noninfected fluid collection requiring either needle aspiration or drain replacement

    Time frame: 90 days

07

Study locations

2 sites
08

References and documents

Publications

  • Nelson JA, Shammas RL, Boe LA, Gonen M, Poulton RT, Stern CS, Rochlin DH, McCarthy CM, Allen RJ Jr, Coriddi M, Disa JJ, Mehrara BJ, Matros E. Two-Stage Prepectoral Breast Reconstruction with and without Acellular Dermal Matrix: A Cluster-Randomized Noninferiority Trial. Plast Reconstr Surg. 2026 Mar 11. doi: 10.1097/PRS.0000000000013019. Online ahead of print. PubMed 41811168 ↗

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Mar 2027, 60 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 60 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 7, 2022
StartActual
Mar 23, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05316324
Collaborators
The Plastic Surgery Foundation
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
Mar 23, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Evan Matros, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion